Cheers to our global gang! 🌍🌟 As the year draws to a close, we're giving a shoutout to the 13,000 amazing contributors on our platform. By leveraging Byron, the exchange within our company becomes more seamless, paving the way for new projects and strengthening our unity within Bayer. 🚀 Presenting this exclusive POAP as a massive thank you, because without you, this platform wouldn't be what it is. 🙌 Byron, an acronym for Bayer Open Network, is our Skills database for Bayer employees, including speed networking. We kicked off in 2018 as a True North grassroots side initiative, going live in 2020. Created by over 40 students and programming enthusiasts with the help of EY Croatia. Today, we have 13,000 registered users from 89 countries, in 293 cities. People have searched for something in Byron at least 25,000 times and engaged in 31,000 1:1 Speed network meetings. http://go/byron Looking ahead, we're thrilled about the future and the prospect of our community growing even larger. Can't wait for more collaborations and successes together in the coming year! 🎉✨ Art created by Lena Schermer

Thanks for for taking the time to complete this survey, It was a pleasure seeing you in Madrid!

Nikola Milosevic is a senior computational scientist at Bayer Pharma R&D, Data Sciences and AI, Data Assets and Insights Solutions team. He is passionate about natural language processing, and therefore a creator of Linguist platform, project owner of NLP@Scale project and involved in HubbleSearch project. He also works on relationship extraction from text for knowledge graphs, and large language models (e.g. Fact Finder). Nikola has a PhD from the University of Manchester (CASE project with AstraZeneca), and previous degrees from University of Belgrade. He has experience with few SAAS startups and smaller companies before joining Bayer in January 2020

Hey! I am a Research Engineer (Data Scientist) in DS&AI > Data Assets and Insights Solutions (DAIS) > Scientific Digital Solutions. I am responsible for implementing scientific solutions (namely: Aelixir, cellenium, ChemogenomicsDB, Bambus ...) and integrating data to make it easily accessibly and analyzable across the Bayer R&D Org. Feel free to reach out : dan.plischke@bayer.com My Professional Experience: Data Scientist: R&D Scientific Digital Solutions September 2020 - Present Corporate Student: Business Information Systems Oktober 2017 - Oktober 2020 My Academic Background: Master of Science - MS, Information Systems · (2020 - now) Humboldt University of Berlin Bachelor of Science - B.Sc., Business Information Systems · (2017 - 2020) The Berlin School of Economics and Law

I studied piano performance and toxicology, and am now Master Data Manager at Bayer Pharma in the R&D Master Data Management team of Data Science & AI. I am passionate about team collaboration and rowing. Currently, I'm co-leading the IDMP Ontology, an international cross-industry project with 12 pharma companies for the unique identification of medicinal products to ensure patient safety. Talk to me about common standards and high quality data for better ML and AI outcomes, our next collaboration project, and/or our next jam session at the Bayer Berlin campus.

I am passionate about harnessing data and cutting-edge technologies to optimize the clinical impact of cancer drugs and diagnostics. Drawing from my personal experiences with cancer, I am devoted to developing analytical systems that integrate clinical, imaging, and biomarker data to provide real-time access to high-quality information. Throughout my career, I have worked closely with clinical teams, advocating for data-driven decision-making and uncovering insights into clinical realities. I strongly believe that by leveraging complex datasets, we can gain a deeper understanding of cancer biology, and subsequently improve our decision-making processes. This adaptable approach empowers us to address fundamental questions, such as which targets to pursue, which technologies to invest in, which drugs to prioritize, and ultimately, which therapies are best suited for individual patients.

I am a curious leader of smart and cool people and together we drive the digital transformation of our Pharma Research and Early development functions.